EmamiQ1 FY24

Emami Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹412.6P/E: 23.9Market Cap: ₹18.0K CrSector: Personal Products

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Targeting around 10% sales growth over the next 2-3 years.
  • International business expected to grow at about 15% in the long term.
  • Male Grooming portfolio anticipated to achieve double-digit growth from Q2 onwards.
  • Healthcare segment (10-12% contribution) expected to deliver double-digit growth.
  • Summer and winter portfolios' performance will influence growth; confident of 6-8% growth in Boro Plus and Navratna.
  • Kesh King portfolio projected to grow around 7-8% annually over the next 2-3 years.
  • Innovation-driven growth estimated at about 3% for the full year.
  • Modern trade and e-commerce channels expected to grow by 15-20%, with e-commerce contribution possibly reaching 25-26% in 2-3 years.
  • Rural recovery expected to further boost sales.
  • Overall confident of 8-10% medium to long-term growth, supported by increased A&P investment and expanded distribution.

See what Emami management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript on page 15 of the provided PDF does not mention any current or future fundraising plans through debt or equity by Emami Limited. Specifically: - There is no discussion about raising new funds via debt or equity. - No comments or guidance were provided by the management regarding such fundraising activities during the Q1 results conference call. - The focus of the discussion was primarily on operational performance, growth strategies, acquisitions, portfolio deseasonalization, and margin expansion. Therefore, based on the available information from the transcript, Emami Limited has not announced any plans for new fundraising through debt or equity as of this call.

See what Emami management said on order book — free account, 30 seconds.

Capex plans

Yes
- The transcript does not explicitly mention any major ongoing or planned capital expenditure (capex) or specific strategic investments. - Focus appears to be on expanding and optimizing existing operations, such as Project Khoj (distribution expansion) which is completed. - Investments are primarily directed towards increased A&P (advertising & promotion) to drive growth, rather than heavy capex. - The management mentions being "very careful" with investment decisions and will wait and watch the seasonal performance before increasing A&P further. - There is a completed acquisition of Dermicool and investments in companies like The Man Company (TMC) and Brillare, contributing around 4-5% to revenues. - Optimism expressed about concluding a hospital transaction by month-end, implying a potential strategic move but no direct capex details provided. - Emphasis on digital/e-commerce and modern trade channels growth, but this seems to be more marketing and channel expansion than capex-heavy. No clear mention of large future capital expenditure plans in the transcript.

Track Emami — get its next earnings analysis in your feed

How does Emami rank vs peers in Personal Products?

Pro feature
ThisEmami
Rev 3Mar 1

How does Emami rank in Personal Products?

Compare Emami against every Personal Products company (Q1 FY24) on revenue, margins and earnings-call signals.

View Personal Products leaderboard →

Others in Personal Products this season

  • Anondita Medicare (Q2 FY27)

    Revenue (Standalone)** for H1 FY27: ₹5,786.31 Lakhs, up 21.43% YoY from ₹4,765.06 Lakhs in H1 FY26 . Key investor presentation takeaways from Anondita Medicare

  • Gillette India (Q2 FY27)

    Revenue from operations for the quarter ended 30th September 2026: ₹84,610 lakh (Page 3) . Key results statement takeaways from Gillette India Ltd's Q2 FY27 ear

  • Cupid (Q2 FY27)

    Q2 FY27 revenue from operations: ₹187.86 Crores, up 122.5% YoY (Q2 FY26: ₹84.45 Crores) [Page 14, 16] . Key investor presentation takeaways from Cupid Ltd's Q2

  • Honasa Consumer (Q2 FY27)

    Younger brands, excluding The Derma Co., are growing healthily at 40%+ year-on-year, with the overall portfolio showing strong momentum across online and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →